### Vinblastine

**Indication**
- Langerhans cell histiocytosis

**INN**
- Vinblastine

**Medicine type**
- Chemical agent

**List type**
- Complementary

**Additional notes**
- For intravenous use only

**Formulations**
- Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)

**EML status history**
- First added in 2023 (TRS 1049)

**Sex**
- All

**Age**
- Also recommended for children

**Therapeutic alternatives**
- The recommendation is for this specific medicine

**Patent information**
- Patents have expired in most jurisdictions

**Tags**
- Cancer

**Wikipedia**
- [Vinblastine](https://en.wikipedia.org/wiki/Vinblastine)

**DrugBank**
- [Vinblastine](https://www.drugbank.ca/drugs/DB00005)

---

**Summary of evidence and Expert Committee recommendations**

The Expert Committee recommended current listings of cytarabine, immunoglobulin, mercaptopurine, methotrexate, prednisolone, vinblastine and vincristine on the complementary list of the EML and EMLc be extended to include the new indication of Langerhans cell histiocytosis (LCH). While LCH is considered a rare disease, the Committee acknowledged that treatment is associated with very high survival rates in many cases. These medicines are recognized as part of the standard of care for children with LCH. Their benefits and harms were accepted as being well established from use in other indications in children and in adults.